#1 Clinical Trials Search in Europe

Pamiparib

Pamiparib is an investigational PARP (poly ADP-ribose polymerase) inhibitor being studied in clinical trials for the treatment of various types of cancer, including ovarian, prostate, and lung cancer. This article summarizes key information about ongoing clinical trials evaluating the safety and efficacy of pamiparib in different cancer types and treatment settings.

Table of Contents

What is Pamiparib?

Pamiparib, also known as BGB-290 or Baihuize, is a new type of cancer medication that belongs to a class of drugs called PARP inhibitors[1][2]. PARP stands for poly(ADP-ribose)-polymerase, which is an enzyme in our cells that helps repair damaged DNA. By inhibiting or blocking this enzyme, Pamiparib can help prevent cancer cells from repairing their DNA, ultimately leading to their death.

How Pamiparib Works

Pamiparib works by targeting cancer cells that have defects in their DNA repair mechanisms, particularly those with mutations in genes called BRCA1 and BRCA2[3]. These mutations are often found in certain types of cancers, such as ovarian and breast cancers. By blocking the PARP enzyme, Pamiparib makes it harder for cancer cells with these mutations to survive and grow.

Cancers Treated with Pamiparib

Pamiparib is being studied for the treatment of several types of cancers, including:

  • Ovarian Cancer: Pamiparib is being investigated for various stages of ovarian cancer, including advanced and recurrent cases[4][5].
  • Breast Cancer: Specifically, triple-negative breast cancer, which is a particularly aggressive form of breast cancer[2].
  • Prostate Cancer: Pamiparib is being studied in patients with metastatic castration-resistant prostate cancer (mCRPC)[3][6].
  • Small Cell Lung Cancer: Research is ongoing for the use of Pamiparib in limited-stage small cell lung cancer[1].

Clinical Trials and Research

Pamiparib is currently being studied in various clinical trials to determine its effectiveness and safety. These trials are investigating different aspects of the drug, including:

  • Its use as a maintenance therapy after chemotherapy in ovarian cancer patients[4].
  • Combining Pamiparib with other treatments, such as Surufatinib for ovarian cancer[7].
  • Its effectiveness in patients who have previously been treated with other PARP inhibitors[4].
  • How the body absorbs, processes, and eliminates Pamiparib[8].

Dosage and Administration

Pamiparib is typically taken orally in the form of capsules. The dosage can vary depending on the specific condition being treated and the clinical trial protocol. Some common dosages reported in the trials include:

  • 40 mg twice daily[1]
  • 60 mg twice daily[4][2]

It’s important to note that these dosages are based on clinical trials and may not reflect the final approved dosage if the drug becomes commercially available. Always follow the instructions provided by your healthcare provider.

Side Effects and Safety

As with all medications, Pamiparib can cause side effects. The full range of potential side effects is still being studied in clinical trials. Common side effects observed in cancer treatments, including PARP inhibitors, may include:

  • Nausea and vomiting
  • Fatigue
  • Decreased blood cell counts
  • Anemia (low red blood cell count)

The safety of Pamiparib is being closely monitored in all clinical trials[4][2]. Patients participating in these trials are regularly assessed for any adverse events or changes in their health status.

Future Prospects

Pamiparib shows promise in the treatment of various cancers, particularly those with specific genetic mutations. Ongoing research is exploring its potential in different cancer types and stages, as well as in combination with other treatments[7][9]. As more clinical trial results become available, we will gain a better understanding of Pamiparib’s effectiveness and safety profile, which could lead to its approval for wider use in cancer treatment.

Cancer Type Trial Phase Treatment Setting Key Outcomes Being Measured
Small cell lung cancer Phase II Consolidation after chemoradiotherapy 1-year progression-free survival rate
Ovarian cancer Phase II After prior PARP inhibitor exposure Clinical benefit rate, progression-free survival
Prostate cancer Phase II Metastatic castration-resistant with HRD or BRCA mutations Radiologic progression-free survival, objective response rate
Ovarian cancer Phase II Neoadjuvant with surufatinib R0 resection rate, overall response rate
Ovarian cancer Phase II Biochemical recurrence during first-line PARP inhibitor maintenance CA-125 response rate, progression-free survival

FAQ

  • What is pamiparib? Pamiparib is an investigational drug that belongs to a class of medications called PARP inhibitors. It works by blocking an enzyme called PARP, which helps repair damaged DNA in cancer cells. By inhibiting PARP, pamiparib may make it harder for cancer cells to survive and grow.
  • What types of cancer is pamiparib being studied for? Pamiparib is being evaluated in clinical trials for several types of cancer, including ovarian cancer, prostate cancer, small cell lung cancer, breast cancer, and other solid tumors. It is being studied both as a single agent and in combination with other treatments.
  • How is pamiparib administered? Pamiparib is taken orally in capsule form. The dosage and frequency vary between trials, but common dosages being studied are 40 mg or 60 mg taken twice daily.
  • What are some of the potential side effects of pamiparib? As with any medication, pamiparib may cause side effects. Common side effects observed in clinical trials include nausea, fatigue, anemia, and decreased appetite. The full safety profile is still being evaluated in ongoing studies.
  • How can I find out if I'm eligible for a clinical trial with pamiparib? Eligibility criteria vary between clinical trials. If you are interested in potentially participating in a pamiparib clinical trial, talk to your oncologist about whether any open trials may be appropriate for you based on your specific diagnosis and treatment history.

Ongoing Clinical Trials on Pamiparib

  • Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland

Glossary

  • PARP inhibitor: A type of targeted cancer drug that blocks an enzyme called poly ADP-ribose polymerase (PARP), which helps repair DNA damage in cells. By inhibiting PARP, these drugs may prevent cancer cells from repairing their damaged DNA, leading to cell death.
  • Homologous recombination deficiency (HRD): A defect in a type of DNA repair process called homologous recombination. Tumors with HRD may be more sensitive to PARP inhibitors.
  • BRCA1/2 mutations: Mutations in the BRCA1 or BRCA2 genes, which are involved in DNA repair. Tumors with BRCA mutations are often deficient in homologous recombination and may be more likely to respond to PARP inhibitors.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Metastatic castration-resistant prostate cancer (mCRPC): Prostate cancer that has spread to other parts of the body and no longer responds to treatments that lower testosterone levels.
  • Circulating tumor cells (CTC): Cancer cells that have detached from a tumor and are found in the bloodstream.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment based on changes in tumor size.

References

  1. https://clinicaltrials.gov/study/NCT05483543
  2. https://clinicaltrials.gov/study/NCT03333915
  3. https://clinicaltrials.gov/study/NCT05327621
  4. https://clinicaltrials.gov/study/NCT05489926
  5. https://clinicaltrials.gov/study/NCT03933761
  6. https://clinicaltrials.gov/study/NCT03712930
  7. https://clinicaltrials.gov/study/NCT05652283
  8. https://clinicaltrials.gov/study/NCT03991494
  9. https://clinicaltrials.gov/study/NCT05669768